PROCLEIX^® WNV Assay

Overview

The PROCLEIX WNV Assay is the leading CE-marked and FDA-approved assay used by blood centers screening for the West Nile virus. Approximately 12 of the 16 million annual donations tested for WNV are tested using the PROCLEIX WNV Assay. Delivering superior sensitivity and specificity, the PROCLEIX WNV Assay reliably detects low-level WNV viral RNA in blood, including all known variants of WNV.

 

 

Benefits

Exceptional performance

• Proven ability to detect WNV at very low viral levels
• Comparable sensitivity for West Nile virus lineage 1 and lineage 2.

 

Maximized utility

The PROCLEIX WNV Assay provides screening protection for:

• Volunteer donors of whole blood and blood components, and from other living donors
• Specimens from organ and tissue donors
• Specimens from cadaveric (non–heart-beating) donors

 

Optimized efficiency with built-in flexibility

• The WNV Assay can be performed on both the PROCLEIX^® System and the PROCLEIX^® TIGRIS^® System and be paired with other PROCLEIX^® Assays. This eliminates the need for additional capital and laboratory space when adding to the portfolio of blood screening tests
• The WNV Assay performed on the PROCLEIX TIGRIS System offers the only self-contained, fully automated platform for NAT screening of West Nile virus
• The WNV assay can be performed using either individual or pooled samples

 

Back to top